Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 29

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Selective Serotonin Reuptake Inhibitor Use and Risk of Gastrointestinal and Intracranial Bleeding

Yuet, Wei Cheng, Derasari, Dhvani, Sivoravong, Jon, Mason, David, Jann, Michael·2019·Journal of Osteopathic Medicine
DOI 10.7556/jaoa.2019.016
Open this paper in CoChat — free account

Abstract

Selective serotonin reuptake inhibitors (SSRIs) are among the most commonly prescribed medications in the United States. Although SSRIs are highly tolerable relative to other antidepressants, they are associated with a number of adverse effects, including increased gastrointestinal tract bleeding and intracranial bleeding. Mechanisms include increased gastric acid secretion and inhibition of serotonin entrance into platelets. Patients with other bleeding risk factors, such as warfarin, clopidogrel, or aspirin use, may be at heightened risk of these adverse effects. The purpose of this article is to review the incidence of gastrointestinal tract bleeding or intracranial bleeding associated with concomitant SSRI use, the proposed mechanisms of, and the potential pharmacokinetic/pharmacodynamic interactions with anticoagulants and antiplatelets. Given the prevalence of SSRI use in the ambulatory setting, osteopathic physicians should be aware of potential drug-drug interactions and the clinical implications of SSRI-associated bleeding risk.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7556/jaoa.2019.016

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 52

  1. Pratt, 2017, Antidepressant Use Among Persons Aged 12 and Over: United States, 2011-2014
  2. Blumner, 2009, Changing perceptions of depression: ten-year trends from the general social survey, Psychiatr Serv., 60, 306, 10.1176/appi.ps.60.3.306 · DOI
  3. Hemeryck, 2002, Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update, Curr Drug Metab., 3, 13, 10.2174/1389200023338017 · DOI · Paper page
  4. Dalton, 2003, Use of selective serotonin reuptake inhibitors and risk of upper gastrointenstinal tract bleeding: a population-based cohort study., Arch Intern Med., 13, 59, 10.1001/archinte.163.1.59 · DOI · Paper page
  5. Bakish, 1997, Effects of selective serotonin reuptake inhibitors on platelet serotonin parameters in major depressive disorder, Biol Psychiatry., 41, 184, 10.1016/S0006-3223(96)00040-6 · DOI
  6. Skop, 1996, Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors, Psychosomatics., 37, 12, 10.1016/S0033-3182(96)71592-X · DOI
  7. Verbeuren, 1989, Synthesis, storage, release and metabolism of 5-hydroxytryptamine in peripheral tissue., 1
  8. Andrade, 2010, Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms, J Clin Psychiatry., 71, 1565, 10.4088/JCP.09r05786blu · DOI · Paper page
  9. Serebruany, 2006, Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something?, Am J Med., 119, 113, 10.1016/j.amjmed.2005.03.044 · DOI
  10. Turner, 2007, Clinical impact of selective serotonin reuptake inhibitors therapy with bleeding risks, J Intern Med., 261, 205, 10.1111/j.1365-2796.2006.01720.x · DOI · Paper page
  11. Coleman, 2016, X-ray structures and mechanism of the human serotonin transporter, Nature., 532, 334, 10.1038/nature17629 · DOI · Paper page
  12. Galan, 2009, Serotonergic mechanisms enhance platelet-mediated thrombogenicity, Thromb Haemost., 102, 511, 10.1160/TH08-12-0810 · DOI
  13. Shen, 1999, Is inhibition of nitric oxide synthase a mechanism for SSRI-induced bleeding?, Psychosomatics., 40, 268, 10.1016/S0033-3182(99)71248-X · DOI
  14. Meijer, 2004, Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants, Arch Intern Med., 164, 2367, 10.1001/archinte.164.21.2367 · DOI · Paper page
  15. Lemberger, 1985, Fluoxetine: clinical pharmacology and physiologic disposition., J Clin Psychiatry., 46, 14
  16. Wong, 1993, Norfluoxetine enantiomers as inhibitors of serotonin uptake in rat brain, Neuropsychopharmacology., 8, 337, 10.1038/npp.1993.33 · DOI
  17. Heym, 1988, Pharmacology of sertraline: a review., J Clin Psychiatry., 49, 40
  18. Ronfeld, 1997, Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers., Clin Pharmacokinet, 32, 22, 10.2165/00003088-199700321-00004 · DOI
  19. Tatsumiab, 1997, Pharmacological profile of antidepressants and related compounds at human monoamine transporters, Eur J Pharmcol, 340, 249, 10.1016/S0014-2999(97)01393-9 · DOI · Paper page
  20. Serebruany, 2001, Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors, Pharmacol Res., 43, 453, 10.1006/phrs.2001.0817 · DOI
  21. Tulloch, 1992, The pharmacologic profile of paroxetine, a new selective serotonin reuptake inhibitor., J Clin Psychiatry., 53, 7
  22. Shahrbabki M, 2014, Sertraline-related bleeding tendency: could it be dose-dependent?, Iran J Psychiatry Behav Sci., 8, 81
  23. Shockley, 1992, Fluoxetine pretreatment potentiates intracisternal TRH analogue-stimulated gastric acid secretion in rats, Regul Pept., 38, 121, 10.1016/0167-0115(92)90050-5 · DOI
  24. Goto, 1985, Gastric erosions induced by intracisternal thyrotropin-releasing hormone (TRH) in rats, Peptides., 6, 153, 10.1016/0196-9781(85)90092-0 · DOI
  25. Nakane, 1985, The effects of centrally administered neuropeptides on the development of gastric lesions in the rat, Life Sci., 36, 1197, 10.1016/0024-3205(85)90238-3 · DOI
  26. Sasek, 1990, Evidence for co-existence of thyrotropin-releasing hormone, substance P and serotonin in ventral medullary neurons that project to the intermediolateral cell column in the rat, Neuroscience., 35, 105, 10.1016/0306-4522(90)90125-N · DOI
  27. LePard, 1994, Serotonin inhibits gastric acid secretion through a 5-hydroxytryptamine1-like receptor in the rat, J Pharmacol Exp Ther., 270, 1139
  28. Lepard, 1996, Gastric antisecretory effect of serotonin: quantitation of release and site of action., Am J Physiol., 271, E669, 10.1152/ajpendo.1996.271.4.E669 · DOI
  29. Salam OM, 2004, Fluoxetine and sertraline stimulate gastric acid secretion via a vagal pathway in anaesthetised rats, Pharmacol Res., 50, 309, 10.1016/j.phrs.2004.01.010 · DOI
  30. Yamaguchi, 2008, The coadministration of paroxetine and low-dose aspirin synergistically enhances gastric ulcerogenic risk in rats, Biol Pharm Bull., 31, 1371, 10.1248/bpb.31.1371 · DOI
  31. Jiang, 2015, Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding: a systematic review and meta-analysis, Clin Gastroenterol Hepatol., 13, 42, 10.1016/j.cgh.2014.06.021 · DOI · Paper page
  32. Laporte, 2017, Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: a meta-analysis of observational studies, Pharmacol Res., 118, 19, 10.1016/j.phrs.2016.08.017 · DOI
  33. de Abajo, 1999, Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study., BMJ., 319, 1106, 10.1136/bmj.319.7217.1106 · DOI · Paper page
  34. Walraven C, 2001, Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study, BMJ, 323, 655, 10.1136/bmj.323.7314.655 · DOI · Paper page
  35. Tata, 2005, Does concurrent prescription of selective sertonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?, Ailment Pharmacol Ther., 22, 175, 10.1111/j.1365-2036.2005.02543.x · DOI
  36. Lewis, 2008, Moderate and high affinity serotonin reuptake inhibitors increase the risk of upper gastrointestinal toxicity, Pharmacoepidemiol Drug Saf., 17, 328, 10.1002/pds.1546 · DOI
  37. Dall, 2009, An association between selective serotonin reuptake inhibitor use and serious upper gastrointestinal bleeding, Clin Gastroenterol Hepatol., 7, 1314, 10.1016/j.cgh.2009.08.019 · DOI · Paper page
  38. Schelleman, 2011, Antidepressant-warfarin interaction and associated gastrointestinal bleeding risk in a case-control study, PLoS One, 6, e21447, 10.1371/journal.pone.0021447 · DOI
  39. Castro, 2012, Incident user cohort study of risk for gastrointestinal bleed and stroke in individuals with major depressive disorder treated with antidepressants, BMJ Open., 2, e000544, 10.1136/bmjopen-2011-000544 · DOI
  40. de Abajo, 2000, Intracranial haemorrhage and use of selective serotonin reuptake inhibitors, Br J Clin Pharmacol., 50, 43, 10.1046/j.1365-2125.2000.00216.x · DOI
  41. Chen, 2009, Hemorrhagic stroke associated with antidepressant use in patients with depression: does degree of serotonin reuptake inhibition matter?, Pharmacoepidemiol Drug Saf., 18, 196, 10.1002/pds.1699 · DOI
  42. Smoller, 2009, Antidepressant use and risk of incident cardiovascular morbidity and mortality among postmenopausal women in the Women's Health Initiative study, Arch Intern Med., 169, 2128, 10.1001/archinternmed.2009.436 · DOI · Paper page
  43. Douglas, 2011, The use of antidepressants and the risk of haemorrhagic stroke: a nested case control study, Br J Clin Pharmacol, 71, 116, 10.1111/j.1365-2125.2010.03797.x · DOI
  44. Verdel, 2011, Use of serotonergic drugs and the risk of bleeding, Clin Pharmacol Ther, 89, 89, 10.1038/clpt.2010.240 · DOI
  45. Renoux, 2017, Association of selective serotonin reuptake inhibitors with the risk for spontaneous intracranial bleeding, JAMA Neurol, 74, 173, 10.1001/jamaneurol.2016.4529 · DOI
  46. O’Connor, 2009, Antidepressant use, depression, and poor cardiovascular outcomes: the chicken or the egg?: comment on “Antidepressant use and risk of incident cardiovascular morbidity and mortality among postmenopausal women in the Women's Health Initiative Study.”, Arch Intern Med., 169, 2140, 10.1001/archinternmed.2009.437 · DOI
  47. Hackham, 2012, Selective serotonin reuptake inhibitors and brain bleeding., Neurol, 79, 1882, 10.1212/WNL.0b013e318271f848 · DOI
  48. Priskorn, 1997, Investigation of multiple dose citalopram on the pharmacokinetics and pharmacodynamics of racemic warfarin, Br J Clin Pharmacol., 44, 199, 10.1046/j.1365-2125.1997.00628.x · DOI
  49. Quinn, 2014, Effect of selective serotonin reuptake inhibitors on bleeding risk in patients with atrial fibrillation taking warfarin, Am J Cardiol., 114, 583, 10.1016/j.amjcard.2014.05.037 · DOI
  50. Chen, 2015, Effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of clopidogrel in rats, Xenobiotica, 45, 1122, 10.3109/00498254.2015.1045570 · DOI
  51. Bykov, 2017, Impact of an interaction between clopidogrel and selective serotonin inhibitors, Am J Cardiol, 119, 651, 10.1016/j.amjcard.2016.10.052 · DOI
  52. Ellero-Simatos, 2014, Pharmacometabolomics reveals that serotonin is implicated in aspirin response variability, CPT Pharmacometrics Syst Pharmacol, 3, e125, 10.1038/psp.2014.22 · DOI

Cited by

Metadata

Authors
Yuet, W. C., Derasari, D., Sivoravong, J., Mason, D., & Jann, M.
Venue
Journal of Osteopathic Medicine
Publisher
Walter de Gruyter GmbH
Published
2019-02-01
Volume
119
Issue
2
Pages
102-111
ISSN
2702-3648
DOI
10.7556/jaoa.2019.016
Cited by
29
References
2
Language
en
Licence
creativecommons.org/licenses/by-nc-nd/4.0 (unspecified)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.